The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...
The following is a summary of “Construction of a machine learning-based interpretable prediction model for acute kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback